|
1
|
Jankowski J, Floege J, Fliser D, Böhm M
and Marx N: Cardiovascular disease in chronic kidney disease.
Circulation. 143:1157–1172. 2021.
|
|
2
|
Alberati-Giani D, Ricciardi-Castagnoli P,
Kohler C and Cesura AM: Regulation of the kynurenine metabolic
pathway by interferon-gamma in murine cloned macrophages and
microglial cells. J Neurochem. 66:996–1004. 1996.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Schefold JC, Zeden JP, Fotopoulou C, von
Haehling S, Pschowski R, Hasper D, Volk HD, Schuett C and Reinke P:
Increased indoleamine 2,3-dioxygenase (IDO) activity and elevated
serum levels of tryptophan catabolites in patients with chronic
kidney disease: A possible link between chronic inflammation and
uraemic symptoms. Nephrol Dial Transplant. 24:1901–1908.
2009.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Eleftheriadis T, Pissas G, Antoniadi G,
Tsogka K, Makri P, Liakopoulos V and Stefanidis I: Increased
indoleamine 2,3-dioxygenase in monocytes of patients on
hemodialysis. Iran J Kidney Dis. 10:91–93. 2016.PubMed/NCBI
|
|
5
|
Saito K, Fujigaki S, Heyes MP, Shibata K,
Takemura M, Fujii H, Wada H, Noma A and Seishima M: Mechanism of
increases in L-kynurenine and quinolinic acid in renal
insufficiency. Am J Physiol Renal Physiol. 279:F565–F572.
2000.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Debnath S, Velagapudi C, Redus L, Thameem
F, Kasinath B, Hura CE, Lorenzo C, Abboud HE and O'Connor JC:
Tryptophan metabolism in patients with chronic kidney disease
secondary to type 2 diabetes: Relationship to inflammatory markers.
Int J Tryptophan Res. 10(1178646917694600)2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
van Gelder MK, Middel IR, Vernooij RWM,
Bots ML, Verhaar MC, Masereeuw R, Grooteman MP, Nubé MJ, van den
Dorpel MA, Blankestijn PJ, et al: Protein-Bound uremic toxins in
hemodialysis patients relate to residual kidney function, are not
influenced by convective transport, and do not relate to outcome.
Toxins (Basel). 12(234)2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Zakrocka I, Wicha-Komsta K, Boczkowska S,
Załuska W, Papadopoulou E and Nasioulas G: The impact of clinical
variables and dialysis modality on kynurenine pathway enzymes
expression. Int J Mol Sci. 27(1313)2026.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Badawy AAB and Guillemin G: The plasma
[Kynurenine]/[Tryptophan] ratio and indoleamine 2,3-dioxygenase:
Time for appraisal. Int J Tryptophan Res.
12(1178646919868978)2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Chen Y, Xie Z, Xiao C, Zhang M, Li Z, Xie
J, Zhang Y, Zhao X, Zeng P, Mo L, et al: Peripheral
kynurenine/tryptophan ratio is not a reliable marker of systemic
indoleamine 2,3-dioxygenase: A lesson drawn from patients on
hemodialysis. Oncotarget. 8:25261–25269. 2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Opitz CA, Litzenburger UM, Sahm F, Ott M,
Tritschler I, Trump S, Schumacher T, Jestaedt L, Schrenk D, Weller
M, et al: An endogenous tumour-promoting ligand of the human aryl
hydrocarbon receptor. Nature. 478:197–203. 2011.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Beischlag TV, Morales JL, Hollingshead BD
and Perdew GH: The aryl hydrocarbon receptor complex and the
control of gene expression. Crit Rev Eukaryot Gene Expr.
18:207–250. 2008.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Eleftheriadis T, Pissas G, Antoniadi G,
Liakopoulos V and Stefanidis I: Kynurenine, by activating aryl
hydrocarbon receptor, decreases erythropoietin and increases
hepcidin production in HepG2 cells: A new mechanism for anemia of
inflammation. Exp Hematol. 44:60–67.e61. 2016.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Eleftheriadis T, Pissas G, Liakopoulos V
and Stefanidis I: IDO decreases glycolysis and glutaminolysis by
activating GCN2K, while it increases fatty acid oxidation by
activating AhR, thus preserving CD4+ T-cell survival and
proliferation. Int J Mol Med. 42:557–568. 2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Eleftheriadis T, Pissas G, Golfinopoulos
S, Liakopoulos V and Stefanidis I: Role of indoleamine
2,3-dioxygenase in ischemia-reperfusion injury of renal tubular
epithelial cells. Mol Med Rep. 23(472)2021.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Razquin C, Ruiz-Canela M, Toledo E,
Hernández-Alonso P, Clish CB, Guasch-Ferré M, Li J, Wittenbecher C,
Dennis C, Alonso-Gómez A, et al: Metabolomics of the
tryptophan-kynurenine degradation pathway and risk of atrial
fibrillation and heart failure: Potential modification effect of
Mediterranean diet. Am J Clin Nutr. 114:1646–1654. 2021.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Dschietzig TB, Kellner KH, Sasse K,
Boschann F, Klüsener R, Ruppert J, Armbruster FP, Bankovic D,
Meinitzer A, Mitrovic V and Melzer C: Plasma kynurenine predicts
severity and complications of heart failure and associates with
established biochemical and clinical markers of disease. Kidney
Blood Press Res. 44:765–776. 2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Guillemin GJ, Lund A, Nordrehaug JE, Lund
A, Nordrehaug JE, Slettom G, Solvang SH, Pedersen EK, Midttun Ø,
Ulvik A, et al: Plasma kynurenines and prognosis in patients with
heart failure. PLoS One. 15(e0227365)2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Pawlak K, Domaniewski T, Mysliwiec M and
Pawlak D: The kynurenines are associated with oxidative stress,
inflammation and the prevalence of cardiovascular disease in
patients with end-stage renal disease. Atherosclerosis.
204:309–314. 2009.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Pawlak K, Brzosko S, Mysliwiec M and
Pawlak D: Kynurenine, quinolinic acid—The new factors linked to
carotid atherosclerosis in patients with end-stage renal disease.
Atherosclerosis. 204:561–566. 2009.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Benitez T, VanDerWoude E, Han Y, Byun J,
Konje VC, Gillespie BW, Saran R and Mathew AV: Kynurenine pathway
metabolites predict subclinical atherosclerotic disease and new
cardiovascular events in chronic kidney disease. Clin Kidney J.
15:1952–1965. 2022.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Al Awadhi S, Myint L, Guallar E, Clish CB,
Wulczyn KE, Kalim S, Thadhani R, Segev DL, DeMarco MM, Moe SM, et
al: A metabolomics approach to identify metabolites associated with
mortality in patients receiving maintenance hemodialysis. Kidney
Int Rep. 9:2718–2726. 2024.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Mohiti S, Christensen J, Landler NE,
Sørensen IM, Thomassen JQ, Bjergfelt SS, Hansen D, Feldt-Rasmussen
B, Bro S, Ebrahimi-Mameghani M, et al: Serum tryptophan and
kynurenine levels and risk of heart failure among patients with
chronic kidney disease. Clin Nutr. 47:14–20. 2025.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Dou L, Poitevin S, Sallée M, Addi T,
Gondouin B, McKay N, Denison MS, Jourde-Chiche N, Duval-Sabatier A,
Cerini C, et al: Aryl hydrocarbon receptor is activated in patients
and mice with chronic kidney disease. Kidney Int. 93:986–999.
2018.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Kolachalama VB, Shashar M, Alousi F,
Shivanna S, Rijal K, Belghasem ME, Walker J, Matsuura S, Chang GH,
Gibson CM, et al: Uremic solute-aryl hydrocarbon receptor-tissue
factor axis associates with thrombosis after vascular injury in
humans. J Am Soc Nephrol. 29:1063–1072. 2018.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Muller AJ, Sharma MD, Chandler PR,
Duhadaway JB, Everhart ME, Johnson BA III, Kahler DJ, Pihkala J,
Soler AP, Munn DH, et al: Chronic inflammation that facilitates
tumor progression creates local immune suppression by inducing
indoleamine 2,3 dioxygenase. Proc Natl Acad Sci USA.
105:17073–17078. 2008.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Mor A, Tankiewicz-Kwedlo A, Ciwun M,
Lewkowicz J and Pawlak D: Kynurenines as a novel target for the
treatment of inflammatory disorders. Cells. 13(1259)2024.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Eleftheriadis T, Pissas G, Antoniadi G,
Spanoulis A, Liakopoulos V and Stefanidis I: Indoleamine
2,3-dioxygenase increases p53 levels in alloreactive human T cells,
and both indoleamine 2,3-dioxygenase and p53 suppress glucose
uptake, glycolysis and proliferation. Int Immunol. 26:673–684.
2014.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Eleftheriadis T, Pissas G, Antoniadi G,
Liakopoulos V and Stefanidis I: Indoleamine 2,3-dioxygenase
depletes tryptophan, activates general control non-derepressible 2
kinase and down-regulates key enzymes involved in fatty acid
synthesis in primary human CD4+ T cells. Immunology. 146:292–300.
2015.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Eleftheriadis T, Pissas G, Sounidaki M,
Tsogka K, Antoniadis N, Antoniadi G, Liakopoulos V and Stefanidis
I: Indoleamine 2,3-dioxygenase, by degrading L-tryptophan, enhances
carnitine palmitoyltransferase I activity and fatty acid oxidation,
and exerts fatty acid-dependent effects in human alloreactive CD4+
T-cells. Int J Mol Med. 38:1605–1613. 2016.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Fang X, Guo L, Xing Z, Shi L, Liang H, Li
A, Kuang C, Tao B and Yang Q: IDO1 can impair NK cells function
against non-small cell lung cancer by downregulation of NKG2D
Ligand via ADAM10. Pharmacol Res. 177(106132)2022.PubMed/NCBI View Article : Google Scholar
|
|
32
|
El-Zaatari M, Chang YM, Zhang M, Franz M,
Shreiner A, McDermott AJ, van der Sluijs KF, Lutter R, Grasberger
H, Kamada N, et al: Tryptophan catabolism restricts
IFN-γ-expressing neutrophils and clostridium difficile
immunopathology. J Immunol. 193:807–816. 2014.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Guo SX, Zhang L, Jiang W and Ma JJ:
Indoleamine 2,3-dioxygenase adjusts neutrophils recruitment and
chemotaxis in Aspergillus fumigatus keratitis. Int J Ophthalmol.
15:380–387. 2022.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Zhao F, Huang Y, Ji J, Liu X, Li X, Zou L,
Wu K, Liu XD, Zeng S, Wang X, et al: IDO1 promotes CSFV replication
by mediating tryptophan metabolism to inhibit NF-κB signaling. J
Virol. 98(e0045824)2024.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Nguyen NT, Kimura A, Nakahama T, Chinen I,
Masuda K, Nohara K, Fujii-Kuriyama Y and Kishimoto T: Aryl
hydrocarbon receptor negatively regulates dendritic cell
immunogenicity via a kynurenine-dependent mechanism. Proc Natl Acad
Sci USA. 107:19961–19966. 2010.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Eleftheriadis T, Liakopoulos V, Antoniadi
G, Stefanidis I and Galaktidou G: Indoleamine 2,3-dioxygenase is
increased in hemodialysis patients and affects immune response to
hepatitis B vaccination. Vaccine. 29:2242–2247. 2011.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Damman K and Testani JM: The kidney in
heart failure: An update. Eur Heart J. 36:1437–1444.
2015.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Melhem NJ, Chajadine M, Gomez I, Howangyin
KY, Bouvet M, Knosp C, Sun Y, Rouanet M, Laurans L, Cazorla O, et
al: Endothelial cell indoleamine 2, 3-dioxygenase 1 alters cardiac
function after myocardial infarction through kynurenine.
Circulation. 143:566–580. 2021.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Wang Y, Song J, Yu K, Nie D, Zhao C, Jiao
L, Wang Z, Zhou L, Wang F, Yu Q, et al: Indoleamine 2,3-dioxygenase
1 deletion-mediated kynurenine insufficiency inhibits pathological
cardiac hypertrophy. Hypertension. 80:2099–2111. 2023.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Sager HB, Hulsmans M, Lavine KJ, Moreira
MB, Heidt T, Courties G, Sun Y, Iwamoto Y, Tricot B, Khan OF, et
al: Proliferation and recruitment contribute to myocardial
macrophage expansion in chronic heart failure. Circ Res.
119:853–864. 2016.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Winkelmayer WC, Patrick AR, Liu J,
Brookhart MA and Setoguchi S: The increasing prevalence of atrial
fibrillation among hemodialysis patients. J Am Soc Nephrol.
22:349–357. 2011.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Nesapiragasan V, Hayıroğlu Mİ, Sciacca V,
Sommer P, Sohns C and Fink T: Catheter Ablation approaches for the
treatment of arrhythmia recurrence in patients with a durable
pulmonary vein isolation. Balkan Med J. 40:386–394. 2023.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Yumurtaş AÇ, Pay L, Tezen O, Çetin T,
Yücedağ FF, Arter E, Kadıoğlu H, Akgün H, Özkan E, Uslu A, et al:
Evaluation of risk factors for long-term atrial fibrillation
development in patients undergoing typical atrial flutter ablation:
A multicenter pilot study. Herz. 50:51–58. 2024.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Takigawa M, Kuwahara T, Takahashi A,
Kobori A, Takahashi Y, Okubo K, Watari Y, Sugiyama T, Kimura S,
Takagi K, et al: The impact of haemodialysis on the outcomes of
catheter ablation in patients with paroxysmal atrial fibrillation.
Europace. 16:327–334. 2013.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Onishi N, Kaitani K, Nakagawa Y, Kobori A,
Inoue K, Kurotobi T, Morishima I, Matsui Y, Yamaji H, Nakazawa Y,
et al: Radiofrequency catheter ablation for atrial fibrillation
patients on hemodialysis (From the Kansai Plus Atrial Fibrillation
Registry)-clinical impact of early recurrence. Circ J.
88:1057–1064. 2024.PubMed/NCBI View Article : Google Scholar
|
|
46
|
van Ham WB, Cornelissen CM, Polyakova E,
van der Voorn SM, Ligtermoet ML, Monshouwer-Kloots J, Vos MA, Bossu
A, van Rooij E, van der Heyden MAG and van Veen TAB: Pro-arrhythmic
potential of accumulated uremic toxins is mediated via
vulnerability of action potential repolarization. Int J Mol Sci.
24(5373)2023.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Eleftheriadis T, Pissas G, Golfinopoulos
S, Liakopoulos V and Stefanidis I: Indoleamine 2,3-dioxygenase
controls purinergic receptor-mediated ischemia-reperfusion injury
in renal tubular epithelial cells. J Basic Clin Physiol Pharmacol.
34:745–754. 2023.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Ye T, Yang J, Liu Z, Yu Y, Zhang C, Guo Y,
Yu F, Zhou Y, Song Z, Shi J, et al: Inhibition of the P2X7 receptor
prevents atrial proarrhythmic remodeling in experimental
post-operative atrial fibrillation. Int Immunopharmacol.
129(111536)2024.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Zhou Y, Ye T, Yu F, Song Z, Wang L, Zhang
C, Yang B, Yang J and Wang X: Inhibition of P2X7 receptor mitigates
atrial fibrillation susceptibility in isoproterenol-induced rats.
Biochem Biophys Res Commun. 749(151340)2025.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Nowak KL and Chonchol M: Targeting
inflammation in CKD. Am J Kidney Dis. 86:803–813. 2025.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Al-Zoubi RM, Elaarag M, Al-Qudimat AR,
Al-Hurani EA, Fares ZE, Farhan A, Al-Zoubi SR, Khan A, Agouni A,
Shkoor M, et al: IDO and TDO inhibitors in cancer immunotherapy:
Mechanisms, clinical development, and future directions. Front
Pharmacol. 16(1632446)2025.PubMed/NCBI View Article : Google Scholar
|
